Welcome to our dedicated page for Axogen news (Ticker: AXGN), a resource for investors and traders seeking the latest updates and insights on Axogen stock.
Axogen Inc. (AXGN) delivers innovative solutions for peripheral nerve repair through clinically validated medical technologies. This dedicated news hub provides investors and healthcare professionals with essential updates on the company developments shaping surgical nerve regeneration.
Access real-time announcements including quarterly earnings reports, regulatory milestones, product launch details, and strategic partnerships. Our curated collection features press releases about Avance Nerve Graft advancements, Axoguard product line expansions, and clinical study outcomes that demonstrate Axogen's leadership in nerve repair innovation.
Bookmark this page for centralized access to financial performance data, research breakthroughs, and market expansion initiatives. Stay informed about Axogen's contributions to improving surgical outcomes through cutting-edge ECM technologies and nerve regeneration solutions.
Axogen, Inc. (NASDAQ: AXGN), a leader in surgical solutions for peripheral nerve injuries, announced plans to release its first quarter 2023 financial results on May 9, 2023, before market opening. Management will conduct a conference call at 8:00 a.m. ET to discuss the results, which investors can join via phone or online. Axogen specializes in technologies for nerve regeneration and repair, with a portfolio that includes products like Avance® Nerve Graft and Axoguard Nerve Connector®. These products are designed to restore nerve function and improve patient quality of life. Axogen's innovations are available in multiple countries, demonstrating its international reach and commitment to patient care.
Axogen reported Q4 2022 revenue of $36.2 million, marking a 17% increase compared to Q4 2021. The company logged a net loss of $5.4 million or $0.13 per share, consistent with the previous year. Adjusted net loss improved to $1.1 million from $3.3 million. The full-year revenue reached $138.6 million, up 12% from 2021. The company anticipates 2023 revenue between $154 million and $159 million. Axogen faced challenges with cash management due to $8 million held at Silicon Valley Bank, which became accessible after the FDIC intervention on March 13, 2023.
FAQ
What is the current stock price of Axogen (AXGN)?
What is the market cap of Axogen (AXGN)?
